Biodefense Market Size, Share & Trends Report

Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/Nuclear), By Region (North America, Latin America, Europe, Asia Pacific, MEA), And Segment Forecasts, 2019 - 2025

  • Published Date: Apr, 2019
  • Base Year for Estimate: 2018
  • Report ID: 978-1-68038-313-3
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 125

Industry Insights

The global biodefense market size was valued at USD 5.47 billion in 2018 and is anticipated to expand at a CAGR of 4.5 % over the forecast period. Rising government initiatives aimed at enhancing the preparedness against Chemical, Biological, Radiological and Nuclear (CBRN) threats is a key factor driving the market. Increased adoption of technologies, such as gene chips for pathogen detection in forensic division, nanotechnology, data base management systems, and advanced detector hardware in biodefense-related drug development is projected to drive the market further.

Significant funding by the U.S. civilian and military organizations, such as Centers for Disease Control and Prevention (CDC), The United States Department of Health & Human Services (HHS), and The Department of Defense (DoD), is also boosting the market growth. Rising prevalence of infectious diseases, such as influenza, is estimated to be one of the key factors boosting the investments for biological threats. In U.S., the federal agency has allocated a considerable budget targeting various biodefense and non-biodefense goals and applications, which are mainly intended to deal with a range of healthcare, public health, national security, and international security issues. These programs conduct scientific research of infectious diseases, create awareness, and improve public health preparedness.

U.S. biodefense market

For instance, as per CDC estimates, between 2016 and 2017, nearly 30 Million people suffered from influenza in the country. Biodefense techniques, such as vaccinations against influenza helps reduce the illness by 17% and medical visits and hospitalizations by 18 to 19% respectively. Growing prevalence of Ebola and Zika virus infections is also likely to contribute to the market development. For instance, as of November 2015, over 28,000 Ebola virus cases and more than 3,800 deaths were reported in Guinea.

Moreover, growing prevalence of congenital Zika virus infection is likely to boost the investments in the field of biodefense. Nuclear or radiation weapons cause destruction due to the harmful effects of ionizing radiation and render damage similar to explosive bombs. CBRN and explosives constitute Weapons of Mass Destruction (WMD) that have the potential to cause annihilation of high magnitude. To mitigate the risk, governments of various countries are actively funding for medical countermeasures against such threats, thereby, positively impacting the global market.

Product Insights

Anthrax accounted for the largest revenue share of 34% in 2018 on account of high investments by the U.S. government for mitigating the risk of anthrax bioterrorism. The segment is expected to continue its dominance over the forecast period owing to increasing funding by the governments of other countries to develop and stockpile sufficient vaccines against anthrax. Biothrax, manufactured by Emergent BioSolutions Inc., is the only FDA-approved vaccine against anthrax for active immunization. The other products segment, which includes chemical and biological products, accounted for the second-largest revenue share in 2018.

Growing focus on mitigating biological threats, such as Ebola and Zika, is a key market driver. As per the data published by the European Union’s report on Member States’ Preparedness for CBRN threats in 2018, the risk of chemical threats is rising owing to easy accessibility of materials and equipment. Thus, increasing funding for chemical threats is also driving the market. Small pox segment is expected to witness the fastest CAGR of 6.2% over the forecast period. Rise in the funding in this area and new products in the clinical pipeline are driving the segment growth.

Regional Insights

North America emerged as the largest regional market accounting for 74.2% of the overall share in 2018. Biodefense strategies undertaken by organizations, such as HHS, BARDA, NIAID, CDC, ASPR, and the FDA, are contributing to the region’s growth. Significant funding by the U.S. military and civilian agencies for biodefense is also one of the key factors responsible for the highest revenue share of the region. However, there are fluctuations in funding due to the changing government policies.

Europe is expected to be the fastest-growing regional market with a CAGR of 6.0% from 2019 to 2025 on account of the rising threat of bioterrorism and increasing R&D investments in countries, such as U.K., Germany, and France. Moreover, better preparedness against CBRN threats by the major European countries is a key factor creating lucrative opportunities in the regional market.

Europe biodefense market

Governments of the Asian countries are also investing in R&D for developing and stockpiling the vaccines and antitoxins for the biological threats. Japan, India, and Australia are the major economies in this region. Strong presence of several organizations, such as Communicable Disease Network Australia (CDNA), that are actively involved in counteracting deliberately released dangerous pathogens and disease outbreaks is also expected to positively impact the region’s growth.

Biodefense Market Share Insights

Some of the key companies in the global biodefense market are Emergent BioSolutions, Inc.; Xoma Corporation; PharmAthene, Inc. (Altimune, Inc.); SIGA Technologies, Inc.; Dynavax Technologies Corporation; Elusys Therapeutics, Inc.; Cleveland Biolabs; Ichor Medical Systems; Dynport Vaccine Company LLC; Achaogen, Inc.; Bavarian Nordic; Nano therapeutics, Inc.; and Alnylam Pharmaceuticals, Inc. Mergers and acquisitions and collaborations with government agencies are the key strategies adopted by these market participants. For instance, in October 2018, Emergent BioSolutions, Inc. acquired PaxVax Holding Company Ltd., the developer and manufacturer of specialty vaccines against infectious diseases.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2025

Market representation

Revenue in USD Million and CAGR from 2019 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Japan, China, India, Australia, Singapore, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global biodefense market report on the basis of product and region:

  • Product Outlook (Revenue, USD Million, 2014 - 2025)

    • Anthrax

    • Small Pox

    • Botulism

    • Radiation/Nuclear

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Spain

      • Italy

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Singapore

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,450
Multi User (2-5) - $6,450
Enterprise Access - $8,450

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified